Atorvastatin and cardiovascular risk in the elderly--patient considerations

about

Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.Safety assessment of concurrent statin treatment and evaluation of drug interactions in China

P2860

Q35929446-9778E90A-870E-40E6-AD16-D662AA35BF05 Q57816047-19631F9E-5FEC-42A8-9E99-C64D52D1A4A8

P2860

Atorvastatin and cardiovascular risk in the elderly--patient considerations

Item

http://www.wikidata.org/entity/Q36897445

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Atorvastatin and cardiovascular risk in the elderly--patient considerations

@en

type

Item

label

Atorvastatin and cardiovascular risk in the elderly--patient considerations

@en

prefLabel

Atorvastatin and cardiovascular risk in the elderly--patient considerations

@en

P1476

Atorvastatin and cardiovascular risk in the elderly--patient considerations

@en

P2093

Francine K Welty

http://www.w3.org/2001/XMLSchema#string

Subroto Acharjee

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home

Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Adherence with statin therapy in elderly patients with and without acute coronary syndromes

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

A receptor-mediated pathway for cholesterol homeostasis

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

P304

299-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18686752

http://www.w3.org/2001/XMLSchema#string

P921

lipid

mechanism of action

coronary artery disease

P932

2546474

http://www.w3.org/2001/XMLSchema#string

Atorvastatin and cardiovascular risk in the elderly--patient considerations

about

P2860

P2860

Atorvastatin and cardiovascular risk in the elderly--patient considerations

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P921

P932